Medicare Enrolled
Dr. Robert Gelfand, M.D.
Hematology & Oncology · New York, NY
Practice pattern: Mixed Practice
— Diverse clinical practice across multiple procedure types
Speaking/Promotional
Very High
DATA COVERAGE
Data in 4 of 4 federal sources
Measures public federal data availability — not provider quality
Informational, not a quality rating.
This page presents federal public records about Dr. Gelfand from CMS (NPPES, Open Payments, Medicare Provider Utilization, PECOS). It is not medical advice, an endorsement, or a judgment of clinical quality. Always consult the provider directly and a licensed clinician for medical decisions. Read methodology →
Are you Dr. Gelfand?
Request a correction or review of any data shown here. Provider portal →
What this data tells you about Dr. Gelfand
Dr. Robert Gelfand is a hematology & oncology specialist in New York, NY, with 20 years of NPI registration. Based on federal Medicare data, Dr. Gelfand performed 353,005 Medicare services across 6,838 unique beneficiaries.
Between the years covered by Open Payments, Dr. Gelfand received a total of $56,394 from 92 pharmaceutical and/or device companies across 1100 individual payments. These payments are legal, publicly disclosed under the federal Sunshine Act, and common in hematology & oncology. The majority of payments are for speaking programs and promotional activities, reflecting participation in industry-sponsored events. Patients may wish to discuss these relationships with their provider.
The Data Coverage level for Dr. Gelfand is Very High — reflecting how much public federal data is available about this provider. Patients are encouraged to use this data as one of several factors when choosing a healthcare provider.
✓ 20 years in practice
▲ Top 0% volume in NY
$56,394 industry payments
Medicare Practice Summary
Medicare Utilization ↗353,005
Medicare services
Top 0% in NY for hematology & oncology
6,838
Unique beneficiaries
$12
Avg. Medicare payment
Medicare patients only (65+ / disabled) · How to read this →
~17,650 Medicare services per year of practice
Top procedures by volume
Ranked by number of services performed for Medicare patients. Avg. submitted charge is what the provider billed; avg. Medicare payment is what CMS paid.
| Procedure | Volume | Avg. paid | Avg. submitted |
|---|---|---|---|
| Romosozumab injection (Evenity) for osteoporosis | 108,150 | $8 | $24 |
| Iron infusion (Feraheme) An injection of ferumoxytol used to treat iron deficiency anemia in patients not on dialysis. |
57,150 | $0 | $7 |
| Denosumab injection (Prolia/Xgeva) | 51,300 | $18 | $112 |
| Iron sucrose injection (Venofer) An injection of iron sucrose used to replenish iron levels in the body. |
24,600 | $0 | $2 |
| Injection, immune globulin, (gamunex-c/gammaked), non-lyophilized (e.g., liquid), 500 mg | 19,350 | $38 | $159 |
| Iron infusion (Injectafer) An intravenous injection of ferric carboxymaltose, an iron replacement medication. |
18,750 | $1 | $2 |
| Daratumumab injection (Darzalex) An injection containing daratumumab and hyaluronidase-fihj administered under the skin. |
18,720 | $38 | $86 |
| Epoetin alfa injection (Retacrit) for anemia An injection of a biosimilar form of epoetin alfa used for non-end-stage renal disease purposes. The dose administered is 1000 units. |
10,800 | $6 | $44 |
| Epoetin alfa injection (Procrit) for anemia An injection of epoetin alfa containing 1000 units for use in patients not on end-stage renal disease (ESRD) dialysis. |
6,260 | $6 | $72 |
| Bortezomib injection, 0.1 mg Administration of a 0.1 mg dose of bortezomib medication via injection. |
5,537 | $4 | $274 |
| Injection, eptinezumab-jjmr, 1 mg | 5,300 | $14 | $30 |
| Dexamethasone injection (steroid) An injection of dexamethasone sodium phosphate, a corticosteroid medication, administered in a dose of 1 milligram. |
4,660 | $0 | $6 |
| Normal saline infusion, 250 cc Administration of 250 cubic centimeters of normal saline solution into a vein. This procedure involves the intravenous delivery of a sterile saltwater fluid. |
2,545 | $1 | $20 |
| Drug injection, under skin or into muscle A procedure involving the administration of a medication or substance via injection into the subcutaneous tissue or muscle. |
1,742 | $13 | $78 |
| Blood draw (venipuncture) Insertion of a needle into a vein to collect a blood sample. |
1,690 | $8 | $30 |
| Complete blood count (CBC) with differential An automated laboratory test that measures the levels of red blood cells, white blood cells, and platelets in the blood, including a breakdown of the different types of white blood cells. |
1,624 | $8 | $87 |
| Injection, benralizumab, 1 mg | 1,620 | $120 | $320 |
| Rituximab biosimilar injection, 10 mg An injection of rituximab-abbs, a biosimilar medication, administered in a 10 mg dose. |
1,540 | $34 | $140 |
| Anti-nausea injection (Aloxi/palonosetron) | 1,384 | $1 | $80 |
| Office visit, established patient (10-19 min) An office visit for an existing patient lasting 10 to 19 minutes. The visit involves medical evaluation and management of the patient's condition. |
1,297 | $50 | $197 |
| Infliximab infusion (Remicade) An injection of infliximab, excluding biosimilar versions, administered in a 10 mg dose. |
1,220 | $26 | $360 |
| Non-hormonal chemotherapy injection This procedure involves administering non-hormonal anti-neoplastic chemotherapy medication via injection into the skin or muscle tissue. |
926 | $69 | $381 |
| Zoledronic acid injection, 1 mg An injection of zoledronic acid administered at a dose of 1 mg. |
871 | $7 | $450 |
| Additional hour of intravenous hydration This code represents each additional hour of intravenous fluid administration beyond the initial hour. It is used to bill for extended hydration therapy. |
853 | $12 | $64 |
| Intravenous infusion, 1 hour or less Administration of medication or fluid directly into a vein for therapeutic, preventive, or diagnostic purposes. The procedure lasts one hour or less. |
793 | $60 | $343 |
| Additional sequential IV infusion, 1 hour or less This code represents an additional intravenous infusion administered sequentially to a primary infusion. It covers the administration time of one hour or less. |
639 | $27 | $148 |
| Office visit, established patient (20-29 min) An office visit for an existing patient lasting between 20 and 29 minutes. The visit involves medical evaluation and management of the patient's condition. |
420 | $82 | $321 |
| Additional hour of intravenous infusion This code represents each additional hour of intravenous infusion beyond the initial hour for therapy, prevention, or diagnosis. |
403 | $19 | $102 |
| Intravenous chemotherapy infusion, 1 hour or less Administration of chemotherapy medication directly into a vein. The procedure takes one hour or less to complete. |
325 | $123 | $676 |
| Office visit, established patient (30-39 min) A follow-up office visit for an existing patient lasting between 30 and 39 minutes. The visit involves medical evaluation and management of the patient's condition. |
316 | $112 | $468 |
| Diphenhydramine injection, up to 50 mg An injection of diphenhydramine hydrochloride, an antihistamine medication, administered in a dose of up to 50 milligrams. |
315 | $1 | $4 |
| New patient office visit (30-44 min) An initial office visit for a new patient lasting between 30 and 44 minutes. This code is used when the total time spent on the date of the encounter falls within this range. |
312 | $98 | $377 |
| Intravenous injection of additional new drug or substance Administration of an additional new medication or substance directly into a vein. |
269 | $15 | $79 |
| Additional hour of intravenous chemotherapy This code represents the administration of chemotherapy medication into a vein for each additional hour beyond the initial period. |
209 | $26 | $145 |
| Injection, sodium ferric gluconate complex in sucrose injection, 12.5 mg | 190 | $2 | $12 |
| Unclassified drug A medication that does not fit into standard HCPCS or CPT classification categories. |
159 | $1 | $20 |
| Vitamin B-12 injection An injection of vitamin B-12 (cyanocobalamin) with a dose of up to 1000 mcg. |
154 | $1 | $18 |
| Normal saline infusion, 1000 cc Administration of 1000 cc of normal saline solution into a vein. This procedure involves the intravenous delivery of a sterile saltwater solution. |
92 | $2 | $38 |
| New patient office visit, complex (60-74 min) | 83 | $198 | $712 |
| New patient office visit (45-59 min) An initial office visit for a new patient lasting between 45 and 59 minutes. This code covers the total time spent by the physician or qualified healthcare professional on the date of the encounter. |
78 | $146 | $567 |
| Heparin sodium injection, per 1000 units An injection of heparin sodium, a blood thinner, administered in units of 1000. |
71 | $0 | $2 |
| Venipuncture for blood collection A procedure to draw blood from a vein for medical testing or analysis. |
61 | $87 | $491 |
| Methylprednisolone injection, up to 125 mg An injection of methylprednisolone sodium succinate, a corticosteroid medication, with a dosage of up to 125 mg. |
55 | $5 | $42 |
| Office visit, established patient, complex (40-54 min) An office or outpatient visit for an existing patient lasting between 40 and 54 minutes. This level of service is determined by the total time spent on the date of the encounter. |
42 | $157 | $627 |
| Intravenous infusion of new drug or substance, 1 hour or less This procedure involves administering a new medication or substance directly into a vein through an existing access site. The infusion is completed within one hour or less. |
28 | $62 | $326 |
| Flu vaccine, quadrivalent A flu shot containing four strains of the influenza virus to help prevent seasonal influenza infection. |
21 | $76 | $150 |
| Flu vaccine administration This procedure involves the administration of the influenza virus vaccine. It covers the process of delivering the vaccine to the patient. |
21 | $35 | $78 |
| Bone marrow aspiration A procedure to remove a small sample of liquid bone marrow for diagnostic testing. |
20 | $74 | $790 |
| Biopsy of bone marrow | 20 | $76 | $729 |
| Bone marrow biopsy and aspiration A procedure to remove a small sample of bone marrow and liquid for laboratory testing. The sample is analyzed to help diagnose various medical conditions. |
20 | $166 | $809 |
How to read this data: This reflects Medicare patients only (typically 65+). Payment amounts are what Medicare paid the provider, not your out-of-pocket cost. A higher procedure volume generally indicates more experience with that procedure.
23.2% high complexity
74.8% medium
2.0% routine
Industry Payment Transparency
Open Payments through 2024 ↗$56,394
Total received (2018-2024)
Avg $8,056/year across 7 years
Top 10% in NY for hematology & oncology
A higher payment rank reflects disclosed industry relationships (consulting, research, speaking) common among subspecialists — not wrongdoing.
92
Companies
1,100
Individual payments
All payments are legal and publicly reported · Not evidence of wrongdoing · How to interpret →
Payment profile
Industry payments classified by relationship type. Not all payments are equal — research and consulting reflect different relationships than speaking programs or meals.
Speaking / Promotional
Speaker programs, honoraria, and industry-sponsored educational events
$32,500 (57.6%)
Meals & Travel
Food, beverages, travel, and lodging — typically low-value
$22,125 (39.2%)
Other
Charitable contributions, space rental, and other categories
$1,769 (3.1%)
Payment trend by year
Annual totals from pharmaceutical and medical device companies.
2024
$3,189
2023
$4,074
2022
$3,314
2021
$4,623
2020
$2,575
2019
$17,191
2018
$21,428
Payments by company (2024)
Consulting
Speaking
Meals & Travel
Research
Lilly USA, LLC
$445
Amgen Inc.
$332
Janssen Biotech, Inc.
$294
Daiichi Sankyo Inc.
$248
GENZYME CORPORATION
$243
Grifols USA, LLC
$171
Genentech USA, Inc.
$123
AstraZeneca Pharmaceuticals LP
$112
Takeda Pharmaceuticals U.S.A., Inc.
$90
Bayer Healthcare Pharmaceuticals Inc.
$89
Novartis Pharmaceuticals Corporation
$87
Celgene Corporation
$84
Regeneron Healthcare Solutions, Inc.
$81
GlaxoSmithKline, LLC.
$78
PFIZER INC.
$67
TerSera Therapeutics LLC
$66
ABBVIE INC.
$58
Eisai Inc.
$42
PUMA BIOTECHNOLOGY, INC.
$40
Octapharma USA, Inc.
$38
Karyopharm Therapeutics Inc.
$37
Amneal Pharmaceuticals LLC
$34
Genmab U.S., Inc.
$33
PharmaEssentia USA Corporation
$29
Alexion Pharmaceuticals, Inc.
$29
Janssen Pharmaceuticals, Inc
$29
Merck Sharp & Dohme LLC
$28
Lundbeck LLC
$26
Gilead Sciences, Inc.
$25
Kyowa Kirin, Inc.
$25
TAIHO ONCOLOGY, INC.
$24
Adaptive Biotechnologies Corporation
$23
SOBI, INC
$23
E.R. Squibb & Sons, L.L.C.
$18
ARRAY BIOPHARMA INC
$16
Top 3 companies account for 33.6% of 2024 payments
All-time payments by company (2018-2024) ›
Takeda Pharmaceuticals U.S.A., Inc.
$32,192
Amgen Inc.
$3,091
Novartis Pharmaceuticals Corporation
$2,380
Janssen Biotech, Inc.
$2,259
AstraZeneca Pharmaceuticals LP
$1,386
GENZYME CORPORATION
$1,093
Lilly USA, LLC
$962
Genentech USA, Inc.
$790
Daiichi Sankyo Inc.
$739
E.R. Squibb & Sons, L.L.C.
$706
Celgene Corporation
$661
Seagen Inc.
$490
GlaxoSmithKline, LLC.
$480
Incyte Corporation
$432
PFIZER INC.
$432
ASD SPECIALTY HEALTHCARE, LLC
$420
Lundbeck LLC
$417
Horizon Therapeutics plc
$402
Merck Sharp & Dohme Corporation
$400
Bayer HealthCare Pharmaceuticals Inc.
$399
Pharmacyclics LLC, An AbbVie Company
$357
Regeneron Healthcare Solutions, Inc.
$338
Puma Biotechnology, Inc.
$291
Teva Pharmaceuticals USA, Inc.
$278
Gilead Sciences, Inc.
$263
Biogen, Inc.
$259
Grifols USA, LLC
$237
Karyopharm Therapeutics Inc.
$225
Clovis Oncology, Inc.
$224
Ipsen Biopharmaceuticals, Inc
$213
Octapharma USA, Inc.
$186
NOVARTIS PHARMACEUTICALS CORPORATION
$167
Janssen Pharmaceuticals, Inc
$166
SOBI, INC
$147
Heron Therapeutics, Inc.
$134
Taiho Oncology, Inc.
$123
Alexion Pharmaceuticals, Inc.
$118
Astellas Pharma US Inc
$114
TerSera Therapeutics LLC
$106
Kyowa Kirin, Inc.
$105
Rigel Pharmaceuticals, Inc.
$102
JAZZ PHARMACEUTICALS INC.
$91
Bayer Healthcare Pharmaceuticals Inc.
$89
Kite Pharma, Inc.
$86
PUMA BIOTECHNOLOGY, INC.
$85
AMAG Pharmaceuticals, Inc.
$83
Pharmacyclics LLC, an AbbVie Company
$73
Merck Sharp & Dohme LLC
$66
Epizyme, Inc.,
$66
Boehringer Ingelheim Pharmaceuticals, Inc.
$64
PharmaEssentia USA Corporation
$62
ABBVIE INC.
$58
Eisai Inc.
$56
EISAI INC.
$55
Exelixis Inc.
$52
TAIHO ONCOLOGY, INC.
$51
Coherus Biosciences Inc.
$51
GRT US Holding, Inc.
$51
Adaptive Biotechnologies Corporation
$50
AbbVie, Inc.
$48
Myovant Sciences Inc.
$48
Mitsubishi Tanabe Pharma America, Inc.
$48
Eagle Pharmaceuticals, Inc.
$47
Apellis Pharmaceuticals, Inc.
$47
Otsuka America Pharmaceutical, Inc.
$42
ARRAY BIOPHARMA INC
$38
MorphoSys, US Inc.
$36
Amneal Pharmaceuticals LLC
$34
AbbVie Inc.
$33
Genmab U.S., Inc.
$33
McKesson Specialty Care Distribution, LLC
$32
ImmunoGen, Inc.
$29
Lexicon Pharmaceuticals, Inc.
$25
AVEO Pharmaceuticals, Inc.
$25
TG THERAPEUTICS, INC.
$25
Foundation Medicine, Inc.
$24
Sun Pharmaceutical Industries Inc.
$24
Mirati Therapeutics, Inc.
$23
Helsinn Therapeutics (U.S.), Inc.
$23
Seattle Genetics, Inc.
$23
Verastem, Inc.
$22
ADC Therapeutics America, Inc.
$22
Sirtex Medical Inc
$22
Dova Pharmaceuticals
$21
Organon LLC
$20
Stemline Therapeutics Inc.
$20
Advanced Accelerator Applications
$17
Emmaus Medical, Inc.
$16
TESARO, Inc.
$15
SANOFI-AVENTIS U.S. LLC
$15
Mylan Institutional Inc.
$14
Allergan Inc.
$14
Top 3 companies account for 66.8% of all-time payments
Associated products mentioned in payments ›
ABECMA · ADCETRIS · ADUHELM · AFINITOR · AKYNZEO · ALIMTA · ALUNBRIG · AVASTIN · AVSOLA · Abraxane · Alecensa · Aliqopa · Avastin · BELRAPZO · BENDEKA · BENLYSTA · BESREMI · BLENREP · BOSULIF · BRAFTOVI · BYNFEZIA PEN · CABLIVI · CABOMETYX · CALQUENCE · CEREZYME · CINVANTI · COSENTYX · CREON · CUTAQUIG · CYRAMZA · Cabometyx · Copiktra · Creon · DALVANCE · DARZALEX · Doptelet · ELIQUIS · ELITEK · EMPLICITI · ENHERTU · ENJAYMO · ENTYVIO · EPKINLY · ERLEADA · EVENITY · EXKIVITY · Elahere · Empaveli · Endari · Enhertu · Erleada · FARESTON · FASENRA · FERAHEME · FOTIVDA · FOUNDATIONONE · Fabhalta · GAMMAGARD · GAZYVA · GILOTRIF · Gamunex-C · HYQVIA · IBRANCE · IMBRUVICA · IMFINZI · INFLECTRA · INJECTAFER · INLYTA · Imbruvica · Inrebic · JADENU · JAKAFI · JAYPIRCA · JEVTANA · KANJINTI · KEYTRUDA · KISQALI · KISUNLA · KRAZATI · KRYSTEXXA · Kyprolis · LIBTAYO · LONSURF · LORBRENA · LUMAKRAS · LUTATHERA · LYNPARZA · Lenvima · Leqembi · Lonsurf · MEKINIST · MONJUVI · MVASI · NERLYNX · NEUPOGEN · NINLARO · NUCALA · Nerlynx · Neulasta · Nplate · Nubeqa · OCREVUS · OCTAGAM · OCTAGAM IMMUNE GLOBULIN (HUMAN) · OJJAARA · OMVOH · OPDIVO · OPDUALAG · ORENCIA · ORGOVYX · Ocrevus · Ogivri · Orserdu · PADCEV · PANZYGA · PIQRAY · POTELIGEO · PROMACTA · Perjeta · Pomalyst · Poteligeo · Prolia · QUZYTTIR · Qutenza · Quzyttir · REBLOZYL · REMICADE · RENFLEXIS · RETEVMO · RYBREVANT · RYDAPT · Radicava · Rezlidhia · Rubraca · Ryanodex · SANCUSO · SANDOSTATIN · SANDOSTATIN LAR · SAPHNELO · SARCLISA · SCEMBLIX · SIMPONI ARIA · SIR-Spheres Microspheres · SKYRIZI · SOLIRIS · SOMATULINE DEPOT · SPRYCEL · STELARA · SUSTOL · Somatuline Depot · Stivarga · TAGRISSO · TALVEY · TASIGNA · TAZVERIK · TECENTRIQ · TECVAYLI · TEPEZZA · TEZSPIRE · TUKYSA · TYSABRI · Tavalisse · Tivdak · Trodelvy · Truxima · UKONIQ · ULTOMIRIS · UPLIZNA · Udenyca · Ultomiris · VENCLEXTA · VERZENIO · VONJO · VYEPTI · Venclexta · XALKORI · XARELTO · XOSPATA · XPOVIO · XTANDI · Xermelo · Xofigo · Yescarta · ZEJULA · ZEPZELCA · ZINPLAVA · clonoSEQ
Should you be concerned? Payments from pharmaceutical and device companies are legal and common — 57% of U.S. physicians receive at least one. They often reflect legitimate consulting, research, or education. What matters is whether a recommended drug or device appears in your doctor's payment records. If so, consider asking your doctor about it. How to interpret this data →
The majority of payments (58%) are for speaking programs and promotional activities, which reflect participation in industry-sponsored educational or marketing events. This is common in hematology & oncology and does not inherently indicate bias, but patients may wish to be aware. Total industry engagement is in the top 10% for hematology & oncology in NY.
Geographic Context
Hematology & oncology specialists within 10 mi
743
Per 100K population
45.6
County median income
$104,553
Nearest hospital
LENOX HILL HOSPITAL
0.6 mi
0.6 mi
Data Sources
| Provider Registry | ✓ NPPES | Weekly updates |
| Medicare Enrollment | ✓ PECOS | Monthly updates |
| Practice Data | ✓ Medicare Util. | Annual (CY lag) |
| Industry Payments | ✓ Open Payments | CY 2024 |
| Disciplinary History | — Not public | N/A |
This provider has data in 4 of 4 available federal datasets, with a Data Coverage level of Very High. This reflects how much public data is available about a provider. How we calculate this →
Summary
Dr. Gelfand is a mixed practice specialist, with above-average Medicare volume (top 0% in NY), with speaking/promotional industry engagement in the top 10% of NY peers, with 20 years of NPI registration.
This summary is auto-generated from federal data, describing data availability and patterns. Read our methodology →
Frequently Asked Questions
Is Dr. Gelfand experienced with romosozumab injection (evenity) for osteoporosis?
Based on Medicare claims data, Dr. Gelfand performed 108,150 romosozumab injection (evenity) for osteoporosis services. Research suggests that higher procedure volume is often associated with better outcomes, particularly for complex procedures. Note that Medicare data only captures patients aged 65 and older, so the total practice volume across all patients is likely higher.
Does Dr. Gelfand receive payments from pharmaceutical companies?
Yes. Dr. Gelfand received a total of $56,394 from 92 companies across 1,100 individual payments. These payments are legal, publicly disclosed under the federal Sunshine Act, and common among physicians — 57% of all U.S. physicians receive at least one industry payment. Patients may wish to ask their doctor about these relationships, especially if a recommended drug or device appears in the payment records.
How do Dr. Gelfand's costs compare to other hematology & oncology specialists in New York?
Dr. Gelfand's average Medicare payment per service is $12. Note that these figures represent what Medicare pays, not your out-of-pocket cost, which depends on your specific insurance plan and deductible. Procedure-level data above shows both what was submitted and what Medicare paid for each service type.
What does Data Coverage mean?
Data Coverage (currently Very High for Dr. Gelfand) measures how much public federal data is available about a provider. It is not a quality rating. A "Very High" or "High" level means the provider has data across multiple federal sources (NPPES, PECOS, Medicare Utilization, Open Payments), indicating a long track record of practice, Medicare participation, and industry disclosure. A "Low" or "Moderate" level may simply mean the provider is newer, does not see Medicare patients, or has not received any industry payments — none of which are inherently negative. Read our full methodology →
Is this data up to date?
Each data source has its own update cycle. Provider registry data (NPPES) is updated weekly. Medicare enrollment (PECOS) is updated monthly. Medicare practice data has a ~2 year lag — the most recent available is typically 2 years prior. Industry payment data (Open Payments) is published annually, usually in June, covering the prior calendar year. We display the data date prominently on each section so you always know how current it is. See our data freshness policy →
Explore related providers
Same specialty & city
Hematology & Oncology Specialists in New York
Browse hematology & oncology specialists in New York ranked by procedure volume and transparency data.
Highest volume
Top Hematology & Oncology Specialists in NY
Hematology & oncology specialists ranked by total Medicare services performed statewide.
Industry payments
Pharma Payments to Hematology & Oncology Specialists in NY
Which NY hematology & oncology specialists receive the most from drug and device companies.
By company
Takeda Pharmaceuticals U.S.A., Inc. Payments to Doctors
See all physicians who received payments from Takeda Pharmaceuticals U.S.A., Inc.
By company
Amgen Inc. Payments to Doctors
See all physicians who received payments from Amgen Inc.
By company
Novartis Pharmaceuticals Corporation Payments to Doctors
See all physicians who received payments from Novartis Pharmaceuticals Corporation.
About this page
All data on this page is sourced verbatim from public federal records published by the U.S. Centers for Medicare & Medicaid Services (CMS): NPPES ↗, Open Payments ↗, Medicare Provider Utilization ↗, and PECOS. Publication is mandated by the Physician Payments Sunshine Act (§6002 ACA, 42 U.S.C. §1320a-7h) and the Freedom of Information Act.
This page is not medical advice, an endorsement, a recommendation, or a quality rating. Data Coverage reflects data completeness — how much federal information exists for this provider — not clinical performance, patient outcomes, or quality of care. Always verify information directly with the provider and consult a licensed clinician before making medical decisions.
Provider corrections: Provider portal · Privacy questions: Privacy Policy · Terms: Terms of Use · Methodology: Methodology